Positive results for pegcetacoplan in C3 glomerulopathy treatment: A step forward in kidney disease research
Apellis Pharmaceuticals has unveiled significant findings from its Phase 2 DISCOVERY clinical trial, offering a ray of hope…
Johnson & Johnson strikes key deal with EC for JNJ-78436735 Covid-19 vaccine supply
Johnson & Johnson (J&J) has announced a significant development in its efforts to combat the Covid-19 pandemic, revealing…
Noxopharm’s Veyonda shows potential in treating severe COVID-19 symptoms in Phase 1 trial
Australian drug development company Noxopharm has embarked on an important milestone in the fight against COVID-19. The company…
Bristol Myers Squibb to acquire MyoKardia for $13.1bn: A strategic move to strengthen cardiovascular portfolio
Bristol Myers Squibb (BMS), a leading global biopharmaceutical company, has announced an agreement to acquire MyoKardia, a California-based…
AstraZeneca’s Farxiga receives FDA breakthrough therapy designation for chronic kidney disease treatment
AstraZeneca’s Farxiga (dapagliflozin), a leading drug in the management of chronic kidney disease (CKD), has been granted Breakthrough…
Kyowa Kirin secures extended EC approval for CRYSVITA in X-linked hypophosphataemia treatment
Kyowa Kirin has recently received expanded approval from the European Commission (EC) for its recombinant monoclonal antibody treatment,…
FDA approves Opdivo and Yervoy combination for malignant pleural mesothelioma treatment
Bristol Myers Squibb (BMS) has secured approval from the US Food and Drug Administration (FDA) for a new…
Novartis reports positive results for Aimovig in phase 2 episodic migraine trial
Novartis said that a five-year phase 2 clinical trial of migraine prevention drug Aimovig (erenumab-aooe) has delivered strong…
Dr. Reddy’s launches Sapropterin Dihydrochloride Tablets generic version in US
Indian pharma company Dr. Reddy’s Laboratories has launched a generic version of phenylalanine hydroxylase activator Sapropterin Dihydrochloride Tablets,…
Covis Group to acquire US biopharma company AMAG Pharmaceuticals
Covis Group, a Luxembourg specialty pharma company, has agreed to acquire US biopharma company AMAG Pharmaceuticals for about…